Scarica l'app Stockscreener
8.983
4.94%
0.423
Dopo l'orario di chiusura:
8.95
-0.033
-0.37%
Precedente Chiudi:
$8.56
Aprire:
$8.52
Volume 24 ore:
34,719
Relative Volume:
0.97
Capitalizzazione di mercato:
$28.55M
Reddito:
-
Utile/perdita netta:
$-68.80M
Rapporto P/E:
-7.6778
EPS:
-1.17
Flusso di cassa netto:
$-59.06M
1 W Prestazione:
+5.43%
1M Prestazione:
+25.76%
6M Prestazione:
+2,328%
1 anno Prestazione:
+1,347%
Intervallo 1D:
$8.125
$9.12
Intervallo di 1 settimana:
$7.13
$9.12
Portata 52W:
$0.257
$9.90
Passage Bio Inc Stock (PASG) Company Profile
Nome
Passage Bio Inc
Settore
Industria
Telefono
(267) 866-0312
Indirizzo
ONE COMMERCE SQUARE, PHILADELPHIA, PA
Confronta PASG con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PASG
Passage Bio Inc
|
8.983 | 27.21M | 0 | -68.80M | -59.06M | -1.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
429.82 | 107.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.32 | 80.03B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.80 | 57.37B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
917.93 | 55.83B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
209.02 | 44.13B | 447.02M | -1.18B | -906.14M | -6.1812 |
Passage Bio Inc Stock (PASG) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-11-29 | Ripresa | Wedbush | Outperform |
| 2024-09-03 | Iniziato | Rodman & Renshaw | Buy |
| 2022-03-08 | Downgrade | JP Morgan | Overweight → Neutral |
| 2022-01-19 | Downgrade | Goldman | Buy → Neutral |
| 2021-07-01 | Iniziato | Raymond James | Outperform |
| 2021-06-15 | Iniziato | BTIG Research | Buy |
| 2021-03-04 | Aggiornamento | Goldman | Neutral → Buy |
| 2021-02-04 | Iniziato | Guggenheim | Buy |
| 2021-01-25 | Iniziato | Wedbush | Outperform |
| 2021-01-04 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2020-12-11 | Iniziato | Citigroup | Neutral |
| 2020-08-14 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-06-25 | Downgrade | Goldman | Buy → Neutral |
| 2020-03-25 | Iniziato | Chardan Capital Markets | Buy |
| 2020-03-24 | Iniziato | Cowen | Outperform |
| 2020-03-24 | Iniziato | Goldman | Buy |
| 2020-03-24 | Iniziato | JP Morgan | Overweight |
Mostra tutto
Passage Bio Inc Borsa (PASG) Ultime notizie
Lucid Capital Markets initiates Passage Bio stock with Buy rating By Investing.com - Investing.com Nigeria
Lucid Capital Markets initiates Passage Bio stock with Buy rating - Investing.com India
Will Salona Cotspin Limited Benefit From Broader Market BounceLow Risk Investment Ideas & Maximize Gains Professionally - earlytimes.in
Passage Bio (PASG) Price Target Decreased by 45.15% to 33.15 - MSN
How Passage Bio Inc. stock compares to market leadersInsider Selling & AI Powered Market Trend Analysis - newser.com
Is Passage Bio Inc. stock bottoming out2025 Volatility Report & Proven Capital Preservation Tips - newser.com
Passage Bio Pushes Toward Key 2026 Milestones as Gene Therapy Program Accelerates - MSN
How Passage Bio Inc. stock reacts to Fed rate cuts2025 Momentum Check & Low Risk High Win Rate Picks - newser.com
Applying chart zones and confluence areas to Passage Bio Inc.2025 Bull vs Bear & Safe Swing Trade Setups - newser.com
What momentum shifts mean for Passage Bio Inc.July 2025 Technicals & Safe Entry Trade Reports - newser.com
Chardan Capital Expects Reduced Earnings for Passage Bio - Defense World
Passage Bio Inc. stock trendline breakdownWeekly Trade Recap & Weekly Return Optimization Alerts - newser.com
Ranking Passage Bio Inc. among high performing stocks via toolsQuarterly Earnings Summary & Long-Term Safe Investment Ideas - newser.com
Passage Bio, Inc.Common Stock (NQ: PASG - FinancialContent
Using economic indicators to assess Passage Bio Inc. potentialQuarterly Earnings Report & Technical Confirmation Trade Alerts - newser.com
How Passage Bio Inc. stock reacts to global recession fearsEarnings Miss & Real-Time Volume Triggers - newser.com
Passage Bio Inc Stock Analysis and ForecastREITs Market Trends & Low Cost Wealth Plans - earlytimes.in
Chardan Capital Raises Passage Bio (NASDAQ:PASG) Price Target to $21.00 - Defense World
Passage Bio (NASDAQ:PASG) Price Target Raised to $21.00 - Defense World
Is Passage Bio Inc. stock a contrarian buyJuly 2025 Final Week & Weekly Stock Breakout Alerts - Fundação Cultural do Pará
What is Wedbush’s Forecast for Passage Bio FY2025 Earnings? - Defense World
Will Passage Bio Inc. price bounce be sustainableJuly 2025 Summary & Low Risk High Reward Ideas - newser.com
Why Passage Bio Inc. stock could rally in 2025Weekly Trend Recap & Stock Portfolio Risk Control - newser.com
Why Passage Bio Inc. stock remains a top recommendationEarnings Growth Report & Low Drawdown Investment Ideas - newser.com
Chardan Capital Raises Price Target on Passage Bio (PASG) to $21 - GuruFocus
Chardan Raises Price Target on Passage Bio to $21 From $6, Keeps Buy Rating - MarketScreener
3 Best Biotech Stocks to Buy Now, 11/12/2025, According to Top Analysts - TipRanks
Chardan Capital Maintains Passage Bio (PASG) Buy Recommendation - MSN
Analysts Offer Insights on Healthcare Companies: Neuren Pharmaceuticals Limited (OtherNURPF) and Passage Bio (PASG) - The Globe and Mail
Passage Bio Cuts Losses And Gains Analysts’ Confidence - Finimize
PASSAGE BIO, INC. Q3 Loss Decreases, Beats Estimates - Nasdaq
Passage Bio (PASG) Advances PBFT02 Clinical Trials and FDA Discu - GuruFocus
[10-Q] Passage BIO, Inc. Quarterly Earnings Report | PASG SEC FilingForm 10-Q - Stock Titan
Passage Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener
Passage Bio Q3 net loss narrows to $7.7 mln - MarketScreener
Passage Bio, Inc. Announces Active Enrollment in upliFT-D Study and Regulatory Alignment with FDA - Quiver Quantitative
PASG: Clinical trial progress, reduced net loss, and strong cash position support future milestones - TradingView
[8-K] Passage BIO, Inc. Reports Material Event | PASG SEC FilingForm 8-K - Stock Titan
Passage Bio (NASDAQ: PASG) narrows net loss to $7.7M, y/y from $19.3M as costs decline - Stock Titan
Passage Bio Inc Azioni (PASG) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.53%
1.88%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):